A phase II evaluation of sunitinib (SU11248) in the treatment of persistent or recurrent clear cell ovarian carcinoma: an NRG oncology / gynecologic oncology group study
Monday, March 30, 2015: 3:08 PM
International Ballroom (Hilton Chicago)
J. K. Chan1, W. E. Brady2, J. Brown3, M. S. Shahin4, P. G. Rose5, J. H. Kim6, A. A. Secord7, J. L. Walker8 and B. J. Monk9
1California Pacific & Palo Alto Medical Foundation / Sutter Research Institute, San Francisco, CA, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3The University of Texas, MD Anderson Cancer Center, Houston, TX, 4Hanjani Institute for Gynecologic Oncology, Abington Memorial Hospital, Abington, PA, 5Cleveland Clinic, Cleveland, OH, 6Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, 7Duke University Medical Center, Durham, NC, 8The University of Oklahoma, Oklahoma City, OK, 9Creighton University School of Medicine and University of Arizona Cancer Center at St. Joseph's Hospital, Phoenix, AZ
